Prostate Cancer Screening: Beyond PSA, Toward Precision
*Corresponding Author: Rita Fernandez, Barcelona Medical Sciences Centre, Spain, Email: rita.fernandez@barcelonameds.esReceived Date: Nov 01, 2025 / Accepted Date: Dec 01, 2025 / Published Date: Dec 01, 2025
Citation: Fernandez R (2025) Prostate Cancer Screening: Beyond PSA, Toward Precision. jcd 09: 330.DOI: 10.4172/2476-2253.1000330
Copyright: © 2025 Rita Fernandez This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricteduse, distribution and reproduction in any medium, provided the original author and source are credited.
Abstract
Prostate cancer screening and diagnosis have shifted toward personalized, multimodal strategies. This approach moves beyond
simpleProstate-Specific \textit{Antigen} (PSA) thresholds, integrating individual factors like age, race, and family history. Advanced
markers such as PSA density and free-to-total PSA ratio improve diagnostic accuracy and guide biopsy decisions. PSA kinetics aid
in active surveillance, while distinguishing benign conditions from cancer remains a challenge. The future involves combining PSA
with imaging and novel biomarkers to optimize risk stratification, minimize overdiagnosis, and facilitate shared decision-making for
tailored patient care.
